Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2026
Long-term outcomes of out-of-hospital cardiac arrest survivors in New Zealand: A prospective, longitudinal cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Parke Rachael L, Eastwood Glenn, Hunt Anna, Turner Anne, Navarra Leanlove, Charles-Nelson Anais, Bailey Michael, McGuinness Shay, TAME study investigators
Аннотация
OBJECTIVE: Out-of-hospital cardiac arrest (OHCA) is a devastating event that can have ongoing neurological and functional sequelae for survivors, which impact their whānau/family and society. Information on long-term survival remains incomplete. We aimed to understand the long-term neurological, functional, and health-related quality of life outcomes and survival of patients with OHCA at 24 months in New Zealand.
DESIGN: We performed a preplanned prospective, longitudinal cohort study. Setting New Zealand Participants Participants enrolled in the Targeted Therapeutic Mild Hypercapnia after resuscitated Cardiac Arrest (TAME trial) in New Zealand.
MAIN OUTCOME MEASURES: Participants had a comprehensive follow-up at 6 and 24 months using the Glasgow Outcome Scale-Extended to determine neurological outcome as well as multiple other patient-centred functional outcome assessment tools.
RESULTS: We included all 200 TAME participants enrolled in New Zealand, of whom 194 (97%) had 24-month data. There was no difference in the primary and secondary TAME study outcomes between groups, with overall 56.3% of participants having a favourable neurological outcome at 6 months. In the New Zealand subpopulation, functional and health-related quality of life status at 24 months was not worse than at 6 months for most survivors, with very few participants reporting more than slight disability.
CONCLUSIONS: Among New Zealand TAME trial participants, neurological and functional outcomes measured across multiple domains generally remained stable or improved between 6 and 24 months. These findings provide important information for survivors of OHCA, their whānau/family, clinicians, and researchers on the timing and trajectory of neurological and functional recovery.
DESIGN: We performed a preplanned prospective, longitudinal cohort study. Setting New Zealand Participants Participants enrolled in the Targeted Therapeutic Mild Hypercapnia after resuscitated Cardiac Arrest (TAME trial) in New Zealand.
MAIN OUTCOME MEASURES: Participants had a comprehensive follow-up at 6 and 24 months using the Glasgow Outcome Scale-Extended to determine neurological outcome as well as multiple other patient-centred functional outcome assessment tools.
RESULTS: We included all 200 TAME participants enrolled in New Zealand, of whom 194 (97%) had 24-month data. There was no difference in the primary and secondary TAME study outcomes between groups, with overall 56.3% of participants having a favourable neurological outcome at 6 months. In the New Zealand subpopulation, functional and health-related quality of life status at 24 months was not worse than at 6 months for most survivors, with very few participants reporting more than slight disability.
CONCLUSIONS: Among New Zealand TAME trial participants, neurological and functional outcomes measured across multiple domains generally remained stable or improved between 6 and 24 months. These findings provide important information for survivors of OHCA, their whānau/family, clinicians, and researchers on the timing and trajectory of neurological and functional recovery.